Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

263 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells.
Bergmann C, Müller F, Distler JHW, Györfi AH, Völkl S, Aigner M, Kretschmann S, Reimann H, Harrer T, Bayerl N, Boeltz S, Wirsching A, Taubmann J, Rösler W, Spriewald B, Wacker J, Atzinger A, Uder M, Kuwert T, Mackensen A, Schett G. Bergmann C, et al. Among authors: mackensen a. Ann Rheum Dis. 2023 Aug;82(8):1117-1120. doi: 10.1136/ard-2023-223952. Epub 2023 May 5. Ann Rheum Dis. 2023. PMID: 37147112 Free PMC article. No abstract available.
Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies.
Taubmann J, Knitza J, Müller F, Völkl S, Aigner M, Kleyer A, Gary R, Kretschmann S, Boeltz S, Atzinger A, Kuwert T, Roemer F, Uder M, Mackensen A, Schett G. Taubmann J, et al. Among authors: mackensen a. Rheumatology (Oxford). 2024 Jan 4;63(1):e12-e14. doi: 10.1093/rheumatology/kead330. Rheumatology (Oxford). 2024. PMID: 37432378 Free PMC article. No abstract available.
Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy.
Nunez D, Patel D, Volkov J, Wong S, Vorndran Z, Müller F, Aigner M, Völkl S, Mackensen A, Schett G, Basu S. Nunez D, et al. Among authors: mackensen a. Mol Ther Methods Clin Dev. 2023 Sep 1;31:101104. doi: 10.1016/j.omtm.2023.08.023. eCollection 2023 Dec 14. Mol Ther Methods Clin Dev. 2023. PMID: 37744005 Free PMC article.
CAR T-cell therapy in autoimmune diseases.
Schett G, Mackensen A, Mougiakakos D. Schett G, et al. Among authors: mackensen a. Lancet. 2023 Nov 25;402(10416):2034-2044. doi: 10.1016/S0140-6736(23)01126-1. Epub 2023 Sep 22. Lancet. 2023. PMID: 37748491 Review.
CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.
Müller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, Völkl S, Aigner M, Rothe T, Minopoulou I, Tur C, Knitza J, Kharboutli S, Kretschmann S, Vasova I, Spoerl S, Reimann H, Munoz L, Gerlach RG, Schäfer S, Grieshaber-Bouyer R, Korganow AS, Farge-Bancel D, Mougiakakos D, Bozec A, Winkler T, Krönke G, Mackensen A, Schett G. Müller F, et al. Among authors: mackensen a. N Engl J Med. 2024 Feb 22;390(8):687-700. doi: 10.1056/NEJMoa2308917. N Engl J Med. 2024. PMID: 38381673
Detection of signature double-negative T cells is a predictive marker to identify autoimmune lymphoproliferative syndrome associated with FAS loss of function.
Eisenhauer N, Miano M, Naumann-Bartsch N, Leyh J, Dell'Orso G, Aigner M, Fecker G, Hinze C, Wittkowski H, Bruns H, Zierk J, Metzler M, Arkwright PD, Graw F, Mackensen A, Völkl S. Eisenhauer N, et al. Among authors: mackensen a. Am J Hematol. 2024 May;99(5):997-1000. doi: 10.1002/ajh.27286. Epub 2024 Mar 14. Am J Hematol. 2024. PMID: 38481382 No abstract available.
Fully Human Anti-CD19 CAR T Cells Derived from Systemic Lupus Erythematosus Patients Exhibit Cytotoxicity with Reduced Inflammatory Cytokine Production.
Dingfelder J, Aigner M, Taubmann J, Minopoulou I, Park S, Kaplan CD, Cheng JK, Van Blarcom T, Schett G, Mackensen A, Lutzny-Geier G. Dingfelder J, et al. Among authors: mackensen a. Transplant Cell Ther. 2024 Mar 26:S2666-6367(24)00297-5. doi: 10.1016/j.jtct.2024.03.023. Online ahead of print. Transplant Cell Ther. 2024. PMID: 38548226 Free article.
263 results